Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTRV ContraVir Pharmaceuticals	$0.04 -2.1%	$3.11	$3.52 ▼ $91.00	$34K	1.16	432,822 shs	235,599 shs
SCPS Scopus BioPharma	$0.00	$0.00	$0.00 ▼ $0.01	$13K	-0.18	1,844 shs	100 shs
SYRS Syros Pharmaceuticals	$0.02 +1,143.8%	$0.01	$0.00 ▼ $0.10	$534K	1.31	186,243 shs	4,661 shs
VRPX Virpax Pharmaceuticals	$0.01 +11.8%	$0.19	$0.01 ▼ $26.25	$15K	1.49	169,058 shs	1,734 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTRV ContraVir Pharmaceuticals	0.00%	0.00%	-34.38%	-45.13%	-94.67%
SCPS Scopus BioPharma	0.00%	0.00%	0.00%	0.00%	+50.00%
SYRS Syros Pharmaceuticals	0.00%	+1,143.75%	-0.50%	-36.01%	-98.84%
VRPX Virpax Pharmaceuticals	0.00%	+11.82%	-38.81%	-94.65%	-99.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTRV ContraVir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SCPS Scopus BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	3.5841 of 5 stars	3.0	5.0	0.0	4.3	0.0	2.5	0.6
VRPX Virpax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTRV ContraVir Pharmaceuticals	0.00	N/A	N/A	N/A
SCPS Scopus BioPharma	0.00	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	2.00	Hold	$1.00	4,925.13% Upside
VRPX Virpax Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTRV ContraVir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.80 per share	N/A
SCPS Scopus BioPharma	N/A	N/A	N/A	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	$386K	1.38	N/A	N/A	$0.79 per share	0.03
VRPX Virpax Pharmaceuticals	N/A	N/A	N/A	N/A	$1.65 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTRV ContraVir Pharmaceuticals	-$9.45M	N/A	0.00	∞	N/A	N/A	-4,810.77%	-130.14%	N/A
SCPS Scopus BioPharma	-$11.61M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	-$164.57M	-$3.03	N/A	N/A	N/A	N/A	-3,369.56%	-97.04%	10/29/2025 (Estimated)
VRPX Virpax Pharmaceuticals	-$15.19M	N/A	0.00	∞	N/A	N/A	-1,554.34%	-338.29%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTRV ContraVir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SCPS Scopus BioPharma	N/A	N/A	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VRPX Virpax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTRV ContraVir Pharmaceuticals	N/A	0.55	0.55
SCPS Scopus BioPharma	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	N/A	2.25	2.25
VRPX Virpax Pharmaceuticals	N/A	0.13	0.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTRV ContraVir Pharmaceuticals	1.07%
SCPS Scopus BioPharma	N/A
SYRS Syros Pharmaceuticals	91.47%
VRPX Virpax Pharmaceuticals	32.23%

Insider Ownership

Company	Insider Ownership
CTRV ContraVir Pharmaceuticals	1.60%
SCPS Scopus BioPharma	5.10%
SYRS Syros Pharmaceuticals	12.26%
VRPX Virpax Pharmaceuticals	3.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTRV ContraVir Pharmaceuticals	14	800,000	N/A	Not Optionable
SCPS Scopus BioPharma	9	42.08 million	39.94 million	Not Optionable
SYRS Syros Pharmaceuticals	120	26.83 million	23.54 million	Optionable
VRPX Virpax Pharmaceuticals	7	1.24 million	4.71 million	Not Optionable

CTRV, SYRS, VRPX, and SCPS Headlines

Recent News About These Companies

Virpax Pharmaceuticals stock plummets on Nasdaq delisting news

April 3, 2025 | investing.com

Virpax Pharmaceuticals Inc trading halted, news pending

March 21, 2025 | markets.businessinsider.com

Virpax reports positive results in Probudur dog study

March 20, 2025 | investing.com

Virpax receives positive Probudur results for dose range study

March 20, 2025 | markets.businessinsider.com

Virpax Pharmaceuticals announces 1-for-25 reverse stock split

March 20, 2025 | markets.businessinsider.com

Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND

March 18, 2025 | finance.yahoo.com

Virpax Pharmaceuticals files to sell common stock and warrants, no amount given

March 18, 2025 | markets.businessinsider.com

Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET

March 11, 2025 | msn.com

Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference

March 11, 2025 | msn.com

Virpax Looking to Use MET to Develop Intranasal COVID Vaccine

March 7, 2025 | businesswire.com

Analysts Conflicted on These Healthcare Names: Clearside Biomedical (CLSD) and Virpax Pharmaceuticals (VRPX)

March 6, 2025 | markets.businessinsider.com

Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS

March 5, 2025 | finance.yahoo.com

Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology

March 3, 2025 | msn.com

Virpax lauds Nanomerics’ MET study with no severe side effects

March 1, 2025 | investing.com

Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology

February 27, 2025 | finance.yahoo.com

Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology

February 27, 2025 | businesswire.com

Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study

February 13, 2025 | joplinglobe.comJ

Virpax Pharmaceuticals confirms results with U.S. Army with Probudur

February 13, 2025 | markets.businessinsider.com

Virpax reports positive study results for pain management drug

February 13, 2025 | msn.com

Virpax Pharmaceuticals appoints new independent director

February 6, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTRV, SYRS, VRPX, and SCPS Company Descriptions

ContraVir Pharmaceuticals NASDAQ:CTRV

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey.

Scopus BioPharma NASDAQ:SCPS

$0.0003 0.00 (0.00%)

As of 08/22/2025 03:19 PM Eastern

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Syros Pharmaceuticals NASDAQ:SYRS

$0.02 +0.02 (+1,143.75%)

As of 08/22/2025 03:18 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Virpax Pharmaceuticals NASDAQ:VRPX

$0.01 +0.00 (+11.82%)

As of 08/22/2025 03:45 PM Eastern

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time